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1. Introduction 
The type IV collagen nephropathies comprise a spectrum of abnormalities predominantly 
affecting the glomerular basement membrane (GBM) in the kidney, but also involving other 
organs such as the ear and eye. Type IV collagen nephropathies result from genetic 
mutations causing loss or deficiency of type IV collagen synthesis, and have been associated 
with Alport syndrome at one end of the spectrum, where individuals who are the most 
severely affected experience end-stage renal failure (ESRF) in their early teen-age years 
together with hearing loss and vision abnormalities. At the other end of the spectrum type 
IV collagen nephropathies are associated with mild defects, such as thin basement 
membrane nephropathy (TBMN) or benign familial hematuria where individuals may 
experience mild kidney abnormalities involving episodic hematuria but retain relatively 
normal renal function and show no extra-renal abnormalities. There are six different type IV 
collagen genes located on multiple chromosomes, and three of these genes (COL4A3, 
COL4A4, and COL4A5) are associated with X-linked, autosomal recessive or autosomal 
dominant  inheritance patterns of Alport syndrome. In addition the type IV collagen genes 
are associated with the TBMN phenotype, involving heterozygous mutations of the COL4A3 
and COL4A4 genes, with an autosomal dominant pattern of inheritance. The main focus of 
this chapter is the mild forms of Alport syndrome, and so in the following pages we review 
mild presentations of Alport syndrome, and illustrate this with a unique New Zealand family 
segregating mild X-linked Alport syndrome, some of whom display features of TBMN. 
2. Synthesis and distribution of type IV collagen  
The type IV collagen family is comprised of six homologous -chains designated 1(IV)–
6(IV) encoded for by the COL4A1-6 genes respectively, the corresponding genes of which 
are located pairwise on chromosomes 13q34, 2q36-37 and Xq22. Each -chain has three 
domains composed of a short 7S domain at the amino terminus, a long collagenous domain 
of approximately 1400 residues of Gly-Xaa-Yaa repeats and a noncollagenous (NC1) domain 
of about 230 residues at the carboxyl terminus (Figure 1). Three  chains assemble into 
triple-helical molecules called protomers that then assemble into supramolecular networks 
by the association of four protomers at the N-terminus, forming a 7S tetramer, and the 
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dimerization of two protomers at the C-terminus, forming an NC1 hexamer (Timpl et al., 
1981). Interruptions in the Gly-Xaa-Yaa amino acid sequence at multiple sites along the 
collagenous domain give rise to flexibility, allowing for looping and supercoiling of 
protomers into networks (Hudson 2004, Miner 2003, Zhou & Reeders 1996). 
 
 
Fig. 1. A schematic drawing showing an example of 3-, 4-, and 5(IV)-chains and 
3.4.5(IV) protomer formation. D: domain 
To date, only three different types of collagen protomer have been identified; 1.1.2(IV), 
3.4.5(IV) and 5.5.6(IV) (Hudson 2004). The protomer 1.1.2(IV) is ubiquitously 
present in most basement membranes (Hudson et al., 1993, Borza et al., 2001, Boutaud et al., 
2000, Timpl et al., 1981). In contrast, 3.4.5(IV) and 5.5.6(IV) show restricted tissue 
distribution. In the kidney the 1.1.2(IV)-1.1.2(IV) network predominates during early 
nephrogenesis in the GBM, the Bowman’s capsular basement membrane, and tubular 
basement membrane. As the kidney becomes mature during the 2nd trimester of fetal 
development, the 3.4.5(IV)-3.4.5(IV) network gradually becomes dominant and 
replaces the 1.1.2(IV)-1.1.2(IV) network in the GBM and in tubular basement 
membranes while the 1.1.2(IV)-5.5.6(IV) and the 1.1.2(IV)-1.1.2(IV) networks 
are distributed in the Bowman's capsular basement membrane and in tubular basement 
membranes (Harvey et al., 1998, Milner 2003). The protomer 3.4.5(IV) is also expressed in 
the lung, testis, cochlea and eye while the 5.5.6(IV) network is present in skin, smooth 
muscle and esophagus (Cosgrove et al., 1998, Hudson et al., 2003, Kalluri et al., 1997). 
Alterations in any of the COL4A3, COL4A4 and COL4A5 genes may cause Alport syndrome.  
3. Alport syndrome 
Alport syndrome is a hereditary disorder with considerable genetic and clinical heterogeneity 
characterized by hematuria, proteinuria (1-2 gm of protein per day) and progressive renal 
failure and is frequently associated with diagnostic ocular abnormalities and high tone 
sensorineural deafness. Ocular abnormalities include lenticonus of the anterior lens capsule, 
retinopathy and cataracts. Other extra-renal manifestations include mental retardation or 
leiomyomatosis in rare cases (Alport 1927, Flinter et al., 1988, Hudson et al., 2003).  
3.1 Genetics 
In approximately 85% of patients with Alport syndrome there is X-linked inheritance of 
mutations in the COL4A5 gene encoding the 5(IV) collagen chain on chromosome Xq22. 
COL4A5 is a large gene comprising 51 exons. As many as 588 mutations have been described 
to date and are spread throughout the gene without any identified mutational hot spots. The 
types of mutations that involve COL4A5 consist of missense, deletion, splice site, nonsense, 
insertion and duplication mutations (Hou et al., 2007, Mochizuki et al., 1994).  
3.4.5. Protomer 
3 
4 
5 
7S-D     Collagenous-D      NC1-D
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The remaining 15% of Alport syndrome patients show autosomal inheritance; of these 14% 
are recessive and 1% are dominant, which are caused by mutations either in the COL4A3 or 
COL4A4 genes on chromosome 2q36-37 encoding the 3(IV) or 4(IV) proteins. 
Heterozygous mutations of COL4A3 or COL4A4 could result in a less severe phenotype than 
that of homozygous or compound mutations in these genes (Jefferson et al., 1997). The 
authors also noted that heterogygous mutations of these genes could result in thin basement 
membrane nephropathy (TBMN) which typically does not result in renal failure. The 
authors postulated that mutations in the COL4A3 or COL4A4 gene can cause a spectrum of 
disease, ranging from TBMN/benign familial hematuria to autosomal dominant and 
recessive forms of Alport syndrome.  
3.2 Pathogenesis 
Ultrafiltration of plasma in the renal glomeruli is the major function of the kidney 
(Voskarides et al., 2008). The primary filtration barrier of the glomerular capillary consists of 
three layers: the fenestrated endothelial cells, the intervening GBM, and the epithelial 
podocyte foot processes. The foot processes are connected to each other by the slit 
diaphragm, and together these constitute an important component of the filtration barrier; 
the loss of podocyte foot processes results in massive proteinuria. The GBM is a special kind 
of acellular extracellular matrix, having properties of a viscous gel. The filtration barrier 
behaves as a selective sieve restricting the passage of macromolecules on the basis of their 
size, shape, and charge. Deterioration of the integrity of the GBM results in mild proteinuria. 
The major constituent of GBM is type IV collagen, which together with laminin, nidogen, 
and sulfated proteoglycans maintains the filtration barrier and provides the substrata and 
signals necessary for proper renal cell function (Hudson & Tryggvason 2003). 
Mutations present in Alport syndrome that produce post-translational defects in 3(IV), 
4(IV), or 5(IV) chains may result in incorrect folding or assembly of monomers. Such 
defective monomers are rapidly degraded. The mutations, therefore, arrest the normal 
developmental maturation during the fetal 2nd trimester period when the 1.1.2(IV) 
network is largely replaced by the 3.4.5(IV) network in the GBM. This maturation may 
be related to oxidative and physical stress in GBM (Kalluri et al., 2000) and perhaps also in 
the cochlea (Huang et al., 2000) and the lens capsule (Reddan et al., 1996). In the kidney, as 
plasma traverses glomerular capillaries, the protein content, including the levels of serum 
proteases, increases. The embryonic 1.1.2(IV) network is more susceptible to 
endoproteolysis than the more heavily cross-linked 3.4.5(IV) network (Kalluri et al 
1997). It seems, then, that GBM that is more exposed to proteases or oxidants needs the 
protection of a resistant collagen IV network. Over time, patients with Alport syndrome 
probably become more sensitive to proteolysis, which may explain why their glomerular 
membranes thicken unevenly, split, and ultimately deteriorate (Kalluri et al., 1997, Kalluri et 
al., 2000). Immunohistochemical studies show that mutations in the COL4A5 gene, which 
cause the X-linked form of Alport syndrome, frequently result in the loss of all three of the 
3(IV), 4(IV) and 5(IV) chains in the GBM (Naito et al., 1996, Naito et al., 2003, Yoshioka 
et al., 1994). Thus, the absence of a functionally normal 5(IV) chain can disrupt assembly of 
the triple-helical protomer, and frequently leads to loss of the entire 3.4.5(IV) network in 
the GBM. 
Mutations involving the NC1 domain of COL4A5 result in no or severely reduced 
3.4.5(IV) protomer formation within cells and/or in failure of secretion from cells 
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(Kobayashi  T et al., 2008, Kobayashi & Uchiyama 2010). In the normal process of formation 
of the type IV collagen network, the NC1 domain plays an important role in forming 
protomers as three chains specifically interact with each other. Additionally, in forming 
NC1 hexamers, two protomers dimerize at the C-terminus. Defective monomers or 
protomers of type IV collagen networks may be degraded rapidly. 
4. Genotype-phenotype correlation in X-linked Alport syndrome 
Approximately six hundred mutations in COL4A5 have been reported, 588 of which are 
causally linked with X-linked Alport syndrome (Arup Laboratories 2011). Considerable 
allelic heterogeneity is observed by the high number of mutations and the associated 
phenotypic variability. Clinically the natural history of the nephropathy and other extra-
renal lesions are quite variable. A number of researchers have attempted to link genotypes 
in Alport syndrome to phenotypes (Bekheirnia et al., 2010, Gross et al., 2002, Jais et al., 2000). 
Gross and colleagues have proposed a classification linking phenotype and genotype into 
three categories (Gross et al., 2002).  
 Type S (severe); genotypic alterations in COL4A5 include major gene rearrangements, 
premature stop codons, frameshift mutations, and donor splice site alterations. Also 
includes mutations involving the NC1 domain. The phenotype is characterised by early 
onset of ESRF at about 20 years of age and significant extra-renal manifestations 
including 80% with sensorineural deafness and 40% with ocular lesions. 
 Type MS (moderately severe). The genotype in this group is characterised by non-
glycine-XY missense alterations, in-frame deletions/insertions, acceptor splice site 
changes and glycine-XY substitutions involving exons 21-47. This type is associated 
with ESRF appearing in the mid-twenties with about 65% of individuals having hearing 
loss and 30% ocular defects. 
 Type M (moderate). The genotype is glycine-XY substitutions involving exons 1-20. The 
phenotype appears to be milder with a later onset of ESRF at about 30 years of age, 
including a significant number of individuals with sensorineural deafness (70%) and 
ocular lesions (30%). 
Bekheirnia and colleagues have confirmed previous reports (Gross et al., 2002, Jais et al., 
2000) in that there is a strong genotype-phenotype correlation in X-linked Alport 
syndrome (Bekheirnia et al., 2010). The authors conclude that missense mutations are 
associated with the best prognosis with an average age at onset of ESRF of 37 yr, followed 
by splice site mutations at 28 yr, truncating mutations at 25 yr and small deletions at 22 
yr. The authors also point out a strong relationship between mutation position and age 
onset of ESRF, with younger ages at onset of ESRF associated with the 5' end of the gene. 
Affected males with splice mutations or truncating mutations showed two-fold greater 
odds of developing eye problems and hearing loss than those with missense mutations. 
Mutations associated with hearing loss and ocular changes are located closer to the 5' end 
of the gene.  
5. Mild forms of Alport syndrome 
While many affected males of X-linked Alport syndrome show moderate to severe forms 
of nephropathy and extra-renal abnormalities between the second and third decades, it is 
also well known that there are occasional milder cases where ESRF may be delayed until 
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the fifth or sixth decade along with variable age occurrence of deafness (Bekheirnia et al., 
2010, Kobayashi et al., 2008, Smeets et al., 1992). Of the six hundred or so COL4A5 
mutations that have been reported to date (Arup Laboratories 2011), 588 mutations were 
pathogenic for X-linked Alport syndrome, whereas 12/600 mutations were benign (silent). 
A total of 81/588 mutations (13.8%) were associated with a mild form of Alport syndrome 
where the age of onset of ESRF was over 30 yr old. These 81 mutations of a mild form are 
shown in Figure 2 and consist of 66 mutations within exons (red column) and 15 
mutations within introns (blue column), widely distributed over the COL4A5 gene. It 
appears that mutations involved in a mild form of Alport syndrome are widely 
distributed within 51 exons of the COL4A5 gene with a tendency for more mutations 
between Exon 25 to 51. 
 
 
Fig. 2. Distribution and frequency of mutations in exons (red column) and introns (blue 
column) within the COL4A5 gene causally relating to X-linked Alport syndrome (Arup 
Laboratories 2011). 
6. A unique mild form of Alport syndrome in New Zealand families 
We previously described a novel Cys1638Tyr alteration in the NC1 domain of COL4A5 
identified in a large New Zealand family (Fig 3) with a hereditary nephropathy (Wilson et 
al., 2007). This family was identified when two sisters (IV26 and IV28) presented to the clinic 
to be considered as potential live kidney donors for their sons (V29 and V35, respectively) 
who had ESRF (see Tables 1 and 2). Both women were found to have significant proteinuria 
and hypertension and so it was decided to carry out renal biopsies. Following the results of 
the biopsies each family member was then evaluated for the presence of renal disease as 
indicated in Table 1, and only three male members of the extensive pedigree were found to 
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exhibit ESRF. Extra-renal manifestations such as sensorineural deafness or ocular changes 
were not observed in any family member. Further renal biopsies were carried out on 
additional family members, so that renal biopsies now totalled eight members of the family. 
The biopsies from a 39 year-old male with proteinuria of 1.1 g/24h and normal auditory and 
eye examination (V42) showed mild increase of mesangial matrix and mild periglomerular 
Bowman capsular fibrosis (Fig 4A). There were occasional areas showing focal interstitial 
accumulation of foam cells (Fig 4B), interstitial fibrosis (Fig 4C) and thick-wall hyalinized 
vessels surrounded by scattered aggregates of lymphocytes (Fig 4D).  
 
 
Fig. 3. Family pedigree. A simplified pedigree of the family showing males (squares) and 
females (circles) depicted by generation (I-V) is shown. While the disease appears severe in this 
pedigree, the extended pedigree was published previously (Wilson et al., 2007), and only 
32/155 members of the extended pedigree are shown in this diagram. Some of the individuals 
indicated in Tables 1 and 2 are represented in this pedigree and are identified in each case by 
their corresponding number. Black symbols indicate individuals with biopsy-confirmed GN. 
Black dots inside the symbols indicate obligate carriers. Grey symbols indicate individuals who 
were not biopsied, with  clinical manifestations of renal disease and therefore presumed GN. 
Open symbols indicate individuals without clinical signs of renal disease. X chromosome region 
markers (Xq21.33-Xq23) informative for linkage analysis are indicated on the right, and shown 
below the symbols are the genotypes for each individual that are associated with the relevant 
marker. The boxed region indicates a common haplotype inherited from the father or the mother, 
corresponding to genotypes of the 3 markers that segregate with the disease. The genomic region 
of chromosome X corresponding to this haplotype contained the COL4A5 gene locus. 
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Identification 
number 
Age 
Gender 
Presentation 
Renal Function and 
Blood Pressure 
Biopsy * Inheritance 
III2 Female  Died on dialysis  Not done 
Affected/ 
Carrier 
IV3 
57 yrs old
male 
 
ESRF at 40 yrs old. 
Dialysis. Renal 
transplant. 
Not done. Affected 
IV5 
46 yrs old 
male 
Proteinuria 
4.7g/24h 
Hypertension 
Chronic kidney 
disease BP 200/120 
Not done Affected 
V24 
39 yrs old 
male 
Proteinuria. 
Hematuria 
BP 148/90 
Mild 
mesangial 
matrix 
expansion 
Affected 
V29 
41 yrs old 
male 
Acute nephritic 
syndrome. 
Hypertension 
ESRF at 28 yrs old. 
Dialysis. 2nd renal 
transplant 
Chronic 
glomerulo-
nephritis 
Affected 
V31 
36 yrs old 
male 
Proteinuria. 
Hypertension 
Chronic kidney 
disease 
BP 136/86 
Mesangial 
cell 
proliferation. 
Affected 
V35 
32 yrs old 
male 
Proteinuria. 
Hematuria 
Chronic kidney 
disease. Progressed 
to ESRF, at 26 yrs 
old and renal 
transplant 
Chronic 
glomerulo-
nephritis 
Affected 
V42 
39 yrs old 
male 
Proteinuria 
1.1g/24 hr 
BP 126/80 
Mesangial 
cell 
proliferation.  
Affected 
* Ig immunofluorescence negative 
Table 1. Renal disease identified prior to mutation screening in the New Zealand family 
Electron microscopy of a renal biopsy from (V42), of which histology is shown in Fig 4, 
demonstrated a classical basket weave pattern or splitting of the basement membrane 
characteristic of Alport syndrome (Fig 5A and 5B). However, a diagnosis of Alport 
syndrome was not necessarily an obvious diagnosis in this family, since the disease in all 
three males was relatively mild and there was a lack of extra-renal manifestations in any of 
the family members, raising some doubts as to whether this was Alport syndrome prior to 
carrying out genetic analysis. 
To determine the genetic cause of the disease in this family, genomic DNA was isolated 
from whole blood of each of the family members, and used in linkage analysis with genetic 
markers spanning chromosome X carried out as described in Wilson et al (2007). Strong 
evidence for linkage to markers DXS6789, DXS8096, DXS1210, adjacent to the COL4A5 (and 
COL4A6) genes located on chromosome X was obtained, indicating that this corresponded 
to a collagen nephropathy in the family, and that it was most likely due to a mutation in 
COL4A5. 
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Identification 
number 
Age 
Gender 
Presentation 
Renal Function and 
Blood Pressure 
Biopsy * Inheritance 
IV24 
69 yrs old
female 
Trace 
microscopic 
hematuria 
Normal renal 
function. 
BP 168/86  
Not done Carrier 
IV26 
64 yrs old
female 
Proteinuria 
1.8g/24 hr 
Hypertension. 
Normal renal 
function 
BP 152/76 
Mesangial cell 
proliferation. 
Hypertensive 
arteriosclerosis 
Affected/ 
Carrier 
IV28 
60 yrs old
female 
Proteinuria 
1.4g/24 hr 
Hypertension 
BP 160/98 
Mesangial cell 
proliferation. 
Hypertensive 
arteriosclerosis 
Affected/ 
Carrier 
IV31 
69 yrs old
female 
Hypertension 
Negative urine 
Normal renal 
function 
Not done Carrier 
IV34 
65 yrs old 
female 
Hypertension 
Negative urine 
Normal renal 
function 
Not done Carrier 
IV36 
61 yrs old 
female 
Microscopic 
hematuria 
Normal renal 
function 
Not done Carrier 
IV39 
72 yrs old 
male 
Proteinuria 
1.6g/24 hr 
No hematuria 
Hypertension 
Mild chronic kidney 
disease 
BP 144/76 
Not done Affected 
IV47 
54 yrs old 
female 
Hematuria 
Hypertension 
Normal renal 
function 
BP 148/70 
Not done Carrier 
V44 
36 yrs old 
female 
Intermittent 
microscopic 
hematuria 
Normal renal 
function 
BP 120/76 
Not done Carrier 
V49 
43 yrs old 
female 
Negative urine 
Normal renal 
function 
BP 120/70 
Not done Carrier 
V37 
39 yrs old
female 
Negative urine 
Normal renal 
function 
Not done Carrier 
V40 
42 yrs old 
female 
Hematuria 
Normal renal 
function.  
BP 118/70. 
Mild 
mesangial cell 
proliferation 
Carrier 
* Ig immunofluorescence negative 
Table 2. Renal disease or carrier status identified after mutation screening in the NZ family 
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Fig. 4. Histological findings of the kidney of a patient, 39 yr old male with hematuria, 
proteinuria 1.1 g/24h and normal auditory and eye examination. (A) Glomerulus from 
kidney biopsy of this patient showing mild periglomerular fibrosis and mild mesangial 
matrix increase. Tubular atrophy is seen at the right upper corner. (B) Focal accumulations 
of foam cells in the interstitium. (C) Multiple focal areas of interstitial fibrosis associated 
with atrophic tubules. (D) Sclerosed vessels surrounded by lymphocytes.  
Eventually the mutation, comprising a c.4913G>A nucleotide substitution in exon 50 of 
COL4A5, was identified by PCR amplification and sequenced following analysis using a 
series of primer pairs corresponding to each of the 51 exons making up the COL4A5 
transcript (Genbank accession number NM_000495) as well as the entire promoter region 
between COL4A5 and COL4A6. Therefore, this analysis conclusively showed that the disease 
in this family was a mild form of Alport syndrome. 
Since it is known that most cases of Alport syndrome result in loss of the synthesis or 
secretion of the collagen protein and/or protomer, which can be detected by the absence of 
the collagen staining by immunohistochemistry, in order to further understand whether the 
pathogenesis of this disease in the New Zealand family was due to the loss of synthesis of 
COL4A5, immunohistochemical studies of the 1 to 5 type IV collagens in kidney biopsies 
from affected and carrier individuals were carried out. This analysis showed that in affected 
men (V31, V35 and V42) and carriers (IV26 and IV28) the GBMs were positive for  to 5 
type IV collagens, as exemplified in Fig 6 (3, 4 and 5). These findings were considerably 
different from the previous reports of Alport syndrome, where the X-linked form of Alport 
A B
C D
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syndrome was generally found to result in the loss of all three of the 3(IV), 4(IV) and 
5(IV) chains in the GBM.   
 
 
 
Fig. 5. Electron microscopy of glomerular basement membranes of the same patient (V42) of 
Figure 4. (A) Characteristic splitting or basket weave appearance of GBM (arrows) and 
abnormal podocyte foot processes. (original magnification x9,700). (B) Higher magnification of a 
basket weave appearance. (original magnification x13,500). Note, the ultra-structural changes in 
the glomerular basement membrane of patients with Alport syndrome were variably associated 
with areas of thick and thin basement membrane, and/or presence of a basket-weave pattern.  
B 
A 
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Fig. 6. Immunohistochemistry using monoclonal antibodies against V collagen in a kidney 
biopsy shows 3, 4 and 5 positivity in the GBM.  
Unlike most other reports of Alport syndrome, and inconsistent with the disease severity 
and multi-organ involvement that is generally associated with NC1 mutations, the major 
manifestation of the renal abnormality in the New Zealand family was proteinuria, which 
occurred in six of the nine male members who carried the COL4A5 mutation. Only three of 
the nine males in the family who inherited the mutation presented with glomerulonephritis 
and ESRF.  
The NC1 domain plays an important role in the selection of  chains for assembly into 
heterotrimers. In general, substitution and missense mutations in the NC1 domain, as in 
other regions of COL4A5, lead to hematuria, proteinuria, ESRF and sensorineural hearing 
loss with an overwhelming predominance in males (Barker et al., 1996, Barker et al., 1997, 
Gross et al., 2002, Hertz et al., 2001, Inoue et al., 1999, Knebelmann et al., 1996, Nakanishi et 
al., 1994, Netzer et al., 1996, Zhou et al., 1991). A previous study classified X-linked Alport 
syndrome patients caused by mutations involving the NC1 domain into Type S (severe) 
phenotype (Gross et al., 2002). Mutations involving other cysteine residues in the NC1 
domain have also been reported and include C1486S (Zhou et al., 1991), C1567R 
(Knebelmann et al., 1996) and C1586R (Hertz et al., 2001) and others (see Figure 7).  
Using the proposed classification suggested by Gross and colleagues, the New Zealand 
family would be placed in ‘type S’ on the basis of the mutant genotype involving the NC1 
domain. However, none of the family members had a phenotype as severe as reported 
previously in association with NC1 domain mutations. In all cases the presentation of renal 
3 4 
5 
www.intechopen.com
 An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
428 
disease in the affected male members of the New Zealand family was relatively late. The 
lack of extra-renal manifestations in the males is also contrary to previous reports 
correlating NC1 mutations with 'type S' Alport syndrome.  
Therefore, while NC1 domain mutations in COL4A5 are thought to be associated with 
severe forms of Alport syndrome, the pattern of disease in this family was comparatively 
mild, and only 27% of the affected or presumed obligate mutant males in the family 
developed end-stage renal disease. Indeed, considerable variability and phenotypic 
heterogeneity in the extent of renal disease was observed in the affected males and carrier 
females. For example, one family member, a 72 year-old male (IV39) shown in Table 2, was 
later found to carry the sequence alteration, and was initially apparently phenotypically 
unaffected, but then further investigation revealed proteinuria (1.6g/24h) and hypertension. 
This man was not biopsied. Furthermore, the presentation of ESRF in one female carrier in 
this study (III2) leads to the conclusion that female carriers were also affected. Skewed 
inactivation of the X chromosome could account for this, although other genetic or 
environmental factors, such as hypertension, could also be contributing factors to the 
variability in disease progression. This amount of phenotypic variation between males and 
females is unusual in Alport syndrome, and even more unusual is the fact that none of the 
family members exhibited the full spectrum of renal, auditory and ocular abnormalities 
typifying Alport syndrome. The inheritance pattern was clearly consistent with an X-linked 
dominant mode, albeit with reduced penetrance, as the linkage analysis, together with the 
scan of the entire COL4A5 gene for the mutation, clearly identified that the NC1 domain 
mutation identified in COL4A5 was the causative mutation in this family.  
The Cys1638Tyr alteration in the New Zealand family is predicted to affect the 10th 
conserved cysteine residue among 12 cysteine residues in the NC1 domain, thus disrupting 
the disulfide bond linking the C-terminal ’-’ hairpin (Fig 7). In the kidney GBM the ’ 
to ’ disulfide-bridge could be involved in inter-molecular rather than intra-molecular 
interactions. For example, inter-protomer disulfide cross-links, or interactions with other 
molecules, such as integrins could involve formation of disulfide linkages to the cysteine 
residues at positions 66, 72, 177 or 183 in the N-terminal or C-terminal - sheets in the 
type IV collagen NC1 domain. 
During protomer assembly the NC1 domains of the 3(IV),4(IV) and 5(IV) chains 
specifically interact to select chains for triple-helix formation. In Alport syndrome, NC1 
domain cysteine substitutions (see Figure 7) are thought to affect the folding of the 
monomeric NC1 domain, preventing its participation in trimer assembly. The NC1 domain 
is also important for network assembly, whereby the NC1 trimers of two protomers 
specifically interact forming a NC1 hexamer. Variants that result in a loss of, or a defect in 
any of the 3(IV), 4(IV), or 5(IV) chains result in incorrect folding or assembly of the 
entire protomer leading to a complete absence of the 3.4.5(IV) network from the GBM. 
However in kidney biopsies from affected patients in this family the 3(IV), 4(IV) and 
5(IV) collagens were still present in the GBM, implying that the p.Cys1638Tyr alteration 
must still allow for the correct assembly of the triple helical protomer. It is possible, 
however, that an organ-specific defect in protomer function rather than assembly could 
explain the lack of sensorineural hearing loss or ocular defects in this family, although it 
remains to be determined whether the p.Cys1638Tyr variant could indeed disrupt the 
dimerization of two protomers at the C-terminus, thus affecting network assembly. 
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Further to the New Zealand family, there have been 7 other mutations involving cysteine 
residues in the NC1 domain (Bekheirnia et al., 2010, Gross et al., 2002, Hertz et al., 2001, 
Inoue et al., 1999, Knebelman et al., 1996, Wang et al., 2005., Wilson et al., 1997, Zhou et al., 
1991) affecting males and females (Figure 7). These mutations are shown together with 
information of age at the time of diagnosis. From refs 2, 3, 6, 7 and 8 patients were detected 
during the ages of 6–16 yrs while one was at 31 yrs old. From refs 3 and 2 two males showed 
ESRF at 14 and 16 yr old, respectively. When clinical information was available, all of the 
affected individuals appeared to show hearing loss, except for three individuals who had 
mutations involving C226 (Wang et al, 2005), C177 (Bekheirnia et al., 2010) and C183 
(Wilson et al., 2007). The latter report is our own New Zealand family described here. 
Patients with other mutations of the NC1 domain either lacked a5(IV) in the GBM, or  were 
clinically more severe than the patients with the C177 and C183 mutations, both of which, 
interestingly involved mutations in the same disulfide linkage.  
 
 
Fig. 7. Depiction of NC1 domain showing locations of cysteine sequence alterations, and the 
clinical details of patients. Shown are the positions of the beta sheet domains (1-6, 1’-6’), 
and alpha helix (1, 1’) and cysteine residues arranged linearly, and their disulfide 
linkages. Cysteine residue missense mutations of the NC1 domain that have been previously 
reported are shown (^), together with the cysteine mutation in the New Zealand family ( 
under cysteine 183; amino acid numbering in this figure is from the start of the NC1 domain, 
which is one amino acid longer than in our previous report (Wilson et al, 1997). ND, not 
determined. +, characteristic is present. -, characteristic is absent. M, male, F, female. Refs; 1 
(Zhou et al., 1991); 2 (Knebelmann et al., 1996); 3 (Hertz et al., 2001); 4 (Bekheirnia et al., 
2010); 5 (Wilson et al., 1997); 6 (Gross et al., 2002), 7 (Inoue et al., 1999); 8 (Wang et al., 2005). 
Kobayashi and colleagues constructed a plasmid containing mutations corresponding to a 
variety of missense or deletion mutations of the NC1 domain of COL4A5, which were grown 
in a kidney cell line. The results showed that mutations render the collagen chain defective 
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in terms of heterotrimer formation between the 3, 4 and 5 collagen chains, and/or the 
secretion of the heterotrimer from cells (Kobayashi et al., 2008). After our publication, these 
researchers further constructed a plasmid containing the mutation corresponding to 
Cys1638Tyr into the 5(IV) chain. The results of this experiment showed that heterotrimer 
formation in the cells and secretion of the 5(IV) chain in the monomeric form from the cells 
were markedly decreased compared to cells containing the wild-type chain. However, the 
heterotrimer that was formed from the mutant chain was still secreted from the cells. They 
concluded that the residual ability of the mutant chain to form and be secreted may have led 
to the unique mild phenotype formed in the Alport syndrome family with the Cys1638Tyr 
mutation (Kobayashi & Uchiyama 2010).  
7. Renal lesions in carrier women of X-linked Alport Syndrome and Thin 
Basement Membrane Nephropathy 
Thin basement membrane nephropathy (TBMN) is the most common cause of inherited 
renal disease and its incidence has been reported to be as high as 1% of the world 
population (Kashtan 2005, Tazon et al., 2003, Wang & Savige 2005). It is defined as diffuse 
thinning of the GBM characterised by persistent glomerular hematuria, minimal proteinuria, 
and normal renal function. Genetic studies of TBMN have helped to establish that many 
patients with benign familial hematuria are actually the carriers of autosomal recessive 
Alport syndrome, carrying mutations only in the one allele of COL4A3 or COL4A4 
(Voskarides et al., 2008). A novel missense mutation of COL4A3 in a Chinese Han 
consanguineous family was identified and the underlying pathogenic role in the 
homozygous form was investigated in autosomal recessive Alport syndrome and in the 
hetrozygous form in TBMN within the identical family (Hou et al., 2007). These studies 
showed that while TBMN manifest as a dominant disorder in the family with the COL4A3 
mutation, Alport syndrome manifested as a recessive disease in the same family. In our 
experience, by light microscopy the kidney glomerular features of the carrier females (eg 
V40) of X-linked Alport syndrome in the New Zealand family were relatively unremarkable. 
However there was occasional periglomerular fibrosis and focal areas of protein casts in 
occasional tubules associated with epithelial cell atrophy (Fig 8A and 8B).  
 
 
   
Fig. 8. Histology from a carrier mother (V40) in the New Zealand family with Alport syndrome. 
(A) Two glomeruli show periglomerular fibrosis. Glomerular tufts are relatively unremarkable. 
(B) Focal areas show protein casts in occasional tubules that show atrophic epithelial cells. 
A  B
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Fig. 9. Electron microscopy of carrier females (V40 and IV28). (A) The same carrier mother 
(V40) of the Figure 8 and (B) another carrier female (IV28), both showing focal areas of 
extremely thin GBM (arrows). (C) In addition there are focal areas of irregular GBM 
thickening. (A x7,400, B x3,000, C x2,100, original magnification respectively). 
Electron microscopic findings on one of the carrier women of the New Zealand X-linked 
Alport syndrome family showed severe thinning of the GBM (Fig 9A) where the thickness 
A  
C B 
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was approximately 150 nm, and much thinner than the normal GBM (300-400 nm). Another 
carrier woman also showed focal areas of severely thin GBM (Fig 9B). In addition there were 
occasional regional areas of thick segments of GBM (Fig 9C). It is notable that the typical 
basket weave appearance or splitting was not present in the females. One message to take 
from these studies is that electron microscopic examination of the kidneys in carrier women 
with clinical symptoms should be mandatory because the light microscopic observations on 
their own often provide unremarkable findings or only subtle changes and may not show a 
full range of pathology. 
Although TBMN has been regarded as a benign condition with an excellent prognosis, as 
high as 38% of COL4A3/COL4A4 heterozygous mutant carriers, of all ages, develop chronic 
renal failure and 19.5% progress to ESRF (Voskarides et al., 2008). These authors emphasize 
a strong association between TBMN and focal segmental glomerulosclerosis (FSGS). Several 
studies report that TBMN predisposes to premature glomerular obsolescence and that this 
may then lead to late onset renal insufficiency followed by ESRF (Nieuhof et al., 1997, 
Nogueira et al., 2000). Other studies suggest that there may be other factors that predispose 
transition from TBMN to FSGS (Sue et al., 2004). These factors could be due to involvement 
of modifier genes such as podocyte specific genes or environmental factors.  
These findings concur with a previous report (Jais et al., 2003) in that hematuria was 
observed in 95% of 323 female carriers of X-linked Alport syndrome. Proteinuria, hearing 
loss, and ocular defects also developed in 75%, 28%, and 15%, respectively. Moreover, the 
probability of developing ESRF or deafness before the age of 40 yr was 12% and 10%, 
respectively, in females versus 90% and 80%, respectively in men. In their study 
ultrastructural change of the GBM were found in 26 of 28 carriers and consisted of typically 
thick and split or alternatively thick and thin GBM in 19 patients. When taken together, our 
results and those of Jais et al (2003) suggest that TBMN may frequently develop in carrier 
women with a heterozygous COL4A5 mutation.  
8. Conclusions  
In conclusion, mild forms of Alport syndrome may occur in association with certain 
mutations in the collagenous domain of the collagen proteins. In addition, we showed a 
p.Cys1638Tyr mutation occurring within the NC1 domain of COL4A5 in a New Zealand 
family was associated with a mild form of Alport syndrome. Mild forms of Alport 
syndrome also occur in females with COL4A5 mutations, in whom there is considerable 
phenotypic variation. In particular, it appears that electron microscopy carried out in female 
carriers of COL4A5 mutations reveals much more about the health of their kidneys than 
does routine light microscopy alone. The abnormalities present in the kidneys of female 
carriers suggest that with appropriate management of diet and hypertension this could 
prevent the onset of renal disease in these women. Additional investigations of the 
pathogenic role of COL4A5 mutations in female members of Alport families, and of the role 
of the NC1 domain in the New Zealand family, will further help to better understand the 
role of collagens in the structure and function of the filtration barrier in the GBM. 
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involvement in some major metabolic and systemic conditions. The final section has chapters which relate to
some general aspects of glomerular diseases. This book will form an excellent reference tool for practicing and
academic nephrology community.
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